NASDAQ:MAZE Maze Therapeutics Q4 2025 Earnings Report $27.68 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$27.69 +0.01 (+0.04%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Maze Therapeutics EPS ResultsActual EPS-$0.65Consensus EPS -$0.73Beat/MissBeat by +$0.08One Year Ago EPSN/AMaze Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMaze Therapeutics Announcement DetailsQuarterQ4 2025Date3/25/2026TimeBefore Market OpensConference Call DateTuesday, March 31, 2026Conference Call Time9:30AM ETConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Maze Therapeutics Earnings HeadlinesMaze Therapeutics, Inc. (NASDAQ:MAZE) Receives $66.00 Consensus Price Target from AnalystsJuly 23, 2026 | americanbankingnews.comMaze Therapeutics Advances MZE782 Phase 2 PKU Trial, Setting Up a New Catalyst for MAZE InvestorsJuly 14, 2026 | tipranks.comPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. | Porter & Company (Ad)What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?June 29, 2026 | finance.yahoo.comMaze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And RiskJune 13, 2026 | finance.yahoo.comMaze Therapeutics Shareholders Elect Directors, Ratify AuditorJune 10, 2026 | tipranks.comSee More Maze Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Maze Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Maze Therapeutics and other key companies, straight to your email. Email Address About Maze TherapeuticsMaze Therapeutics (NASDAQ:MAZE) (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic. Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas. By integrating large‐scale genetic datasets with functional genomics assays, the company seeks to uncover previously unrecognized pathways that can be modulated by small molecules or biologics. Its target selection strategy is designed to deliver higher confidence in clinical proof‐of‐concept studies, and Maze’s research collaborations with academic and industry partners support the advancement of its most promising candidates through preclinical and early clinical stages. Headquartered in South San Francisco, California, Maze Therapeutics operates within a vibrant biotech cluster and draws on a network of scientific advisors and strategic collaborators worldwide. The company is led by a management team with extensive experience in genomics, drug development and translational research. By focusing on genetically validated targets and a disciplined go-to-clinic approach, Maze aims to bring transformative therapies to patients in need while creating value for its shareholders.View Maze Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/20- 07/24Telecom Earnings Reveal a Sector That Finally Looks HealthierAMD and Cerbras Create A New Blueprint For HardwareIntel Earnings Reveal Whether the Chip Selloff Created a BuyRTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?Broadcom May Be the Biggest Winner From Alphabet's EarningsDefense Earnings Show Readiness Now and Modernization Ahead Upcoming Earnings PACCAR (7/28/2026)Ford Motor (7/28/2026)Boeing (7/28/2026)Ecolab (7/28/2026)Rio Tinto (7/28/2026)Sherwin-Williams (7/28/2026)Visa (7/28/2026)Waste Management (7/28/2026)Corning (7/28/2026)KLA (7/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
